Aluminum Hydroxide

Evidence Level: N/A

Predicted Indications: 0

---

Table of Contents

1. Aluminum Hydroxide
   1. Pharmacist Assessment Report
   2. Aluminum Hydroxide: Known uses and market status in Canada
   3. Summary
   4. Quick overview
   5. Known uses among the model’s candidates
      1. Approved (supported by a licence or label)
      2. Related to an approved indication (same disease category)
      3. Relations recorded in the knowledge graph (no approval found)
   6. Canada Market Information
   7. Safety Considerations
   8. Disclaimer

---

Pharmacist Assessment Report

Aluminum Hydroxide: Known uses and market status in Canada

Summary

The TxGNN deep-learning model produced candidate indications for Aluminum Hydroxide, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The known uses are listed below by the type of support they have.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	4
Evidence level	Not applicable
Canada Market Status	Marketed (marketed DINs: 2 of 2)
Number of DINs	2 (marketed: 2)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Related to an approved indication (same disease category)

Indication	Approved category
gastroduodenitis	gastritis

Relations recorded in the knowledge graph (no approval found)

Indication
active peptic ulcer disease
gastrojejunal ulcer
peptic ulcer perforation

Canada Market Information

Licence	Product	Dosage form	Status
00623709	STOMAAX PLUS		Valid
00815527	ALMAGEL PLUS SUS		Valid

Safety Considerations

Drug Interactions: 100 interactions were recorded. The main ones are:

• Major: dolutegravir, sodium citrate
• Moderate: acalabrutinib, doxycycline, alendronic acid, risedronic acid, allopurinol, amphetamine, ascorbic acid, acetylsalicylic acid, atazanavir, proguanil
• Minor: famotidine, ranitidine, acebutolol, atenolol, atorvastatin, alprazolam, hydrocortisone, triamcinolone

Published reviews also describe phosphate depletion and bone demineralisation with long-term high-dose aluminum hydroxide (PMID 6293043, PMID 2257522).

Please refer to the package insert for warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.

---